Once-weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9-GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm™ trials.

Johannes OldenburgManuel D CarcaoSteven R LentzJohnny N MahlanguMaria Elisa MancusoTadashi MatsushitaClaude NégrierWan Hui Ong ClausenSilke EhrenforthGuy Aaron Young

Published in: Haemophilia : the official journal of the World Federation of Hemophilia (2018)

N9-GP 40 IU/kg once-weekly was well tolerated and effective in preventing bleeding, maintaining mean FIX activity levels ≥15% across all age groups. N9-GP may provide a new treatment option for preventing bleeding in haemophilia B patients.

Keyphrases

end stage renal disease
atrial fibrillation
ejection fraction
prognostic factors
electronic health record
randomized controlled trial
machine learning
artificial intelligence
combination therapy